GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”, or “the company”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity. Alongside the clearance, the company also announced the product’s full commercial launch.
Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch
1 min read Premium comments
510(k) clearanceShoulder InnovationsFDAN-22 Humeral Headfull commercial
Approximately 10% to 15% of the general population test positively for metal hypersensitivity and may experience persistent pain, or other symptoms associated with allergic reactions from metal implants. The N-22 Humeral Head is designed for use in anatomic total shoulder arthroplasty procedures involving patients with these complications and complements the company’s N-22 Glenosphere implant, cleared in January 2026, which is used in reverse total shoulder arthroplasty procedures involving the same patient population.
“The N-22 Humeral Head augments our line of technologies for patients with metal hypersensitivity, now providing surgeons with a metal-sensitive option across both shoulder arthroplasty configurations,” said Rob Ball, CEO of Shoulder Innovations. “As we continue to expand our commercial footprint across the U.S., even small incremental additions to our product line can have a meaningful impact on our relationships with surgeons and operating centers.”
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com
SOURCE Shoulder Innovations
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Shoulder Innovations secured FDA 510(k) clearance and initiated full commercial launch for its N-22 Humeral Head, a titanium implant for metal-sensitive patients in anatomic total shoulder arthroplasty. This strategic move expands their specialized product offering, complementing the N-22 Glenosphere for reverse procedures. The company aims to enhance surgeon relationships and market presence by addressing a niche patient population, reinforcing its focused growth strategy in the shoulder surgical care market.
- The N-22 Humeral Head's full commercial launch expands Shoulder Innovations' specialized product line for metal-sensitive patients, enhancing market penetration.
- This incremental product addition supports the company's strategy to strengthen surgeon relationships and grow its commercial footprint in the shoulder arthroplasty market.
PhD Lens: Clinical and outcomes impact
Shoulder Innovations received FDA 510(k) clearance for the N-22 Humeral Head, a titanium implant designed for anatomic total shoulder arthroplasty. This device targets patients with metal hypersensitivity, a condition affecting 10-15% of the population, who may experience persistent pain or allergic reactions from traditional metal implants. It expands the company's offerings for this specific patient demographic, complementing an existing glenosphere implant.
- The N-22 Humeral Head is a titanium implant specifically indicated for anatomic total shoulder arthroplasty in metal-hypersensitive patients.
- It addresses a patient population (10-15%) prone to adverse reactions from conventional metal implants, expanding specialized options for shoulder arthroplasty.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.